Evaluation of Oral PF614 Relative to OxyContin (PF614-102)

Inclusion Criteria: * Males or females, ages 18-50 years in good general health, * BMI between 18 and 32 kg/m (inclusive) * Subjects must have a negative screen for drugs of abuse, nicotine, alcohol, Hepatitis B, Hepatitis C, and HIV. * Female subjects of child bearing potential must have a negative serum pregnancy test at randomization * Females must be of non-child bearing potential (e.g. postmenopausal) or of childbearing potential and agree to use a highly effective form of contraception from the time of screening to two weeks after last dose of study medication. * Subjects must have normal findings in a physical examination and 12 lead ECG and normal Vital Signs * Clinical laboratory values must be Within Normal limits as defined by the clinical laboratory * Subjects must be able to provide coherent written informed consent * Subjects must be willing and able to follow study instructions and be likely to complete all study requirements. Exclusion Criteria: * History of allergy or sensitivity to oxycodone * History of loud snoring or sleep apnea * History of medical problems encountered with opioid therapy * Urinary cotinine levels indicative of smoking or history of smoking or regular tobacco use with 2 months prior to screening * History of alcoholism or drug abuse * Use of prescription medications within 14 days of study drug administration with exception of contraceptives used by female subjects * Use of any opioid within 30 days prior to screening * History of allergy or sensitivity to naltrexone * History of allergy or sensitivity to naloxone * Donation of blood within 30 days prior to screening * Donation of plasma within 30 days prior to screening * Acute illness at admission of clinical study unit * History of GI disturbance requiring use of antacid twice weekly or more * Females who are breastfeeding * Anticipated need for surgery or hospitalization during the study * Enrollment in an investigational drug study within 30 days prior to screening * Any condition that in the Investigator's opinion puts the subject at significant risk, could confound the study results, or may interfere significantly with the subject's participation in the study.